Silexion Therapeutics to Initiate Phase 2/3 Clinical Trial for SIL204 in H1 2026 Following Strong Preclinical Data and Regulatory Feedback
SLXN sits 43% above its 52-week low of $1.65 on elevated volume (2.2× avg).
Summary
Silexion Therapeutics announced significant progress for its lead asset, SIL204, including positive preclinical data, successful toxicology studies, and regulatory feedback, positioning the RNAi therapy for a Phase 2/3 clinical trial initiation in H1 2026 for locally advanced pancreatic cancer.
Key Events · Product Development and Regulatory · SLXN
-
Phase 2/3 Clinical Trial Initiation
Silexion Therapeutics plans to initiate a Phase 2/3 clinical trial for its lead asset, SIL204, in locally advanced pancreatic cancer during the first half of 2026, following regulatory submissions in Israel.
-
Positive Preclinical Data
SIL204 demonstrated significant tumor inhibition (>90%) and activity across eight distinct KRAS mutations and five cancer types in preclinical studies, including reduction of primary tumor growth and metastatic spread.
-
Regulatory Progress
The company completed toxicology studies and received positive Scientific Advice from Germany's BfArM on its Phase 2/3 trial design, with further regulatory submissions planned for Germany, the EU, and the U.S. in 2026.
-
Substantial 2025 Financing
Silexion Therapeutics raised over $18 million in aggregate financing during 2025, providing significant capital to support its clinical development and operational runway.
Analysis · SLXN · Life Sciences
This 8-K filing, containing a CEO letter to shareholders, provides a comprehensive and highly positive update on Silexion Therapeutics' lead RNAi therapy, SIL204. The company has achieved critical milestones, including compelling preclinical data demonstrating significant tumor inhibition across multiple cancer types and mutations, successful completion of toxicology studies, and positive regulatory feedback from Germany for its Phase 2/3 trial design. The planned initiation of a Phase 2/3 clinical trial in H1 2026 for locally advanced pancreatic cancer represents a major value inflection point and de-risking event for the clinical-stage biotechnology company. Furthermore, the disclosure of over $18 million in financing raised during 2025 is substantial for a company of this market capitalization, providing crucial capital for advancing its clinical development pipeline. Investors should monitor the upcoming regulatory submissions and the commencement of the clinical trial as key catalysts.
At the time of this filing, SLXN was trading at $2.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.9M. The 52-week trading range was $1.65 to $51.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.